Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Paul S. who wrote (457)	4/24/1998 4:57:00 PM
From: Eric Hathaway	Read Replies (1) \| Respond to of 1185

To All, Yahoo shows NDRTF last at US$2.00, with the bid at 1.875 and the ask at 3.75 what gives with this? Oh, just checked carlson, here it is: Attention Business Editors: NORTRAN PHARMACEUTICALS INC. ANNOUNCES BROKERED PRIVATE PLACEMENT CO-LED BY CANACCORD CAPITAL CORP. AND GORDON CAPITAL CORP., WITH GOEPEL MCDERMID INC. PARTICIPATING VANCOUVER, April 24 /CNW/ - Nortran Pharmaceuticals Inc. VSE: NRT; NASD BB: NTRDF Nortran Pharmaceuticals Inc. announces a brokered private placement to be co-led by Canaccord Capital Corp. and Gordon Capital Corp., with Goepel McDermid Inc. participating, to raise on a best efforts basis, gross proceeds of $10,500,000. The private placement will consist of 5,000,000 special warrants at $2.10 each. Each special warrant will be exercisable, without payment of additional consideration, into one unit comprised of one common share of Nortran and one half of one non-transferable common share purchase warrant. Each whole share purchase warrant will entitle the holder to purchase an additional common share of Nortran at $2.50 for one year from the date of closing of the private placement. In consideration for the service performed by the Agents, Nortran will pay the Agents a cash fee equal to 7.0 % of the proceeds of the offering and will issue agent's warrants entitling the Agents to purchase such number of shares of Nortran equal to 10% of the number of special warrants sold. Each agent's warrant will have the same terms as the common share purchase warrants forming part of the units. The net proceeds of the offering will be used for preclinical and clinical trials, upgrades and acquisitions of laboratory equipment, computers and building facilities as well as to provide working capital for operations. The securities have not and will not be registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption form registration requirements. On March 18, 1998, Nortran granted, subject to VSE approval, incentive stock options entitling an employee of the Company to purchase an aggregate of 600,000 common shares of the Company at a price of $1.49 per share. Nortran Pharmaceuticals Inc. is a drug discovery company whose focusing on pathology targeted small molecules. Nortran's current drugs in development target the ion channels responsible for life-threatening arrhythmias of the heart and for intractable pain. ON BEHALF OF THE BOARD ''Bob Rieder'' Robert W. Rieder Chief Executive Officer THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. %SEDAR: 00003146E -30- For further information: Sue Milne, Investor Relations, (604) 222-5577, Toll Free: 800-330-9928, Fax: (604) 222-6617, Website: www.nortran.com NORTRAN PHARMACEUTICALS INC. has 8 releases in this database.

To: Paul S. who wrote (457)	4/24/1998 6:23:00 PM
From: Wisee	Read Replies (1) \| Respond to of 1185

Paul, I too phoned the IR people at Nortran, and got the same response as you did. I don't know who Saracen is, but I do know that today was his first day on Silicon Investor. Hmmmmm??? Was NRT around five years ago??? We are all speculating on NRT!!! Should be interesting next week, Wisee